Overview

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

Status:
Suspended
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or docetaxel.
Phase:
Phase 1
Details
Lead Sponsor:
Human Genome Sciences Inc., a GSK Company
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Docetaxel
Etoposide
Etoposide phosphate
Immunoglobulin G
Paclitaxel